Skip to main content
PEP-TRIPLE-GLP1 • RESEARCH USE ONLY

Triple Agonist / GLP-1

A synergistic nasal peptide blend combining a Triple Agonist (GLP-1, GIP, and glucagon pathways) with GLP-1 to deliver amplified fat metabolism, appetite regulation, and energy balance. This formulation is designed to provide broader metabolic signaling than GLP-1 alone while remaining suitable for daily use.

25 mg / 40 mg

Per Bottle
156 mcg / 250 mcg per spray

>99%

Purity
Third-party verified

160

Sprays per bottle

Disclaimer: Dosing guides are provided as suggestions for prescribed use only in countries where the use of the respective peptides is legally permitted. These guides have not been approved by any regulatory authority and are not intended to constitute medical advice.

Protocol & Dosing

Use once or twice daily, preferably morning or before high-risk eating periods. Nasal Spray clears rapidly and therefore requires consistent daily dosing for best results.

Starting
125 mcg (1 spray)
Standard
250 mcg (2 sprays)
Medium
375 mcg (3 sprays)
Higher
500 mcg (4 sprays)
Key Benefits

Promotes efficient glucose utilization, supports appetite regulation, enhances metabolic balance, improves fat-to-energy conversion, and supports steady daily focus and energy when used consistently.

Guidance
  • Start with 1 spray, then wait 24–48 hours to assess appetite response
  • Increase slowly only if needed
  • Once your "sweet spot" is found, remain consistent at that dose until you feel an adjustment is necessary
  • Do not exceed 4 sprays per day unless directed
  • Best used daily or every other day, not sporadically
  • Can be used alone or alongside lifestyle changes
PROPRIETARY DELIVERY TECHNOLOGY

Zenith Nano™ Spray System

Nasal delivery is facilitated with the Zenith Nano™ Spray System — a proprietary liquid ion delivery platform engineered for enhanced bioavailability, deep tissue penetration, and improved compound stability without compromising safety. Unlike carriers that rely on encapsulation, it enables direct solubilization and optimized partitioning of actives including peptides and coenzymes — no liposomes, no lipid nanoparticles, no emulsifier-dependent payloads. Built from amino acids and endogenous molecules for biocompatibility; scalable across routes that include intranasal sprays.

Lipid disruption & cation exchange
Alkyl chains intercalate into the stratum corneum lipid matrix via hydrophobic interactions, reducing cohesion and increasing permeability. Cationic components displace native ions such as Ca²⁺ within lipid lamellae, weakening structural integrity so actives pass through more efficiently.
Dual-polarity solubilization
Hydrophilic and lipophilic character solubilizes and transports a broad range of actives directly — without emulsifiers or encapsulating carriers.
Keratin modulation & partitioning
Temporarily denatures keratin within corneocytes, opening transient micro-pathways for epithelial migration. Improves solubility and skin partitioning while maintaining proprietary differentiation for IP — inspired by systems like CAGE (choline–geranic acid ionic liquids).
Superior loading vs. lipid carriers
Solubilizes actives directly instead of inefficient encapsulation. In-house studies: lipid-based carriers penetrated only ~22 μm — insufficient for meaningful absorption — whereas the Zenith Nano™ Spray System reaches therapeutically relevant layers.
>57× vs. saline · <10 nm (DLS)
>57× barrier penetration vs. saline in an ex vivo epithelial model (Zenith Nano™ third-party data). Minimum confirmed nanoparticle size under 10 nm — mucus-penetrating ionic clusters by dynamic light scattering.
Safety, stability & distribution
ISO 10993-5 CCK-8 assay: 80–100% viability at 24 h and 48 h. Four-month room-temperature stability: 101.1–101.9% HPLC recovery — no cold chain. In vivo oral mouse study: systemic distribution across five organs at 1 hour post-dose.

Compliance · Zenith Nano™ Peptides

cGMP manufacturing & cryopreservation

Manufactured through Pacific Manufacturing & Design LLC — GMP-certified under NSF/ANSI 455-2 and FDA-registered (Reg. No. 15492349536). Compliant with 21 CFR Parts 11, 111, and 117. Strict quality control, validated processes, and full traceability from raw material to final product.

NSF/ANSI 455-2FDA REGISTERED21 CFR PART 11121 CFR PART 117
Third-Party COA — Every Batch

Third-party COA for every batch, ensuring consistent quality and purity. Verified through LCMS and endotoxin testing, with full traceability from raw material to final product.

LCMS CONFIRMED>99% PURITYENDOTOXIN TESTEDAXISPHARM COA